ETNB241115C10000
- 0.60
- +0.20+50.00%
89bio Newsroom
Raymond James Maintains Strong Buy on 89bio, Lowers Price Target to $49
89bio Analyst Ratings
RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Maintains Target Price $12
89bio (ETNB) Gets a Hold From RBC Capital
89bio GAAP EPS of -$1.39 Misses by $0.78
89bio | 10-Q: Q3 2024 Earnings Report
Express News | 89Bio Q3 Basic EPS USD -1.39
Express News | 89Bio Q3 Operating Income USD -151.938 Million Vs. IBES Estimate USD -68.5 Million
Press Release: 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
Calendar of U.S. Earnings Expected in the Week Ahead
89bio to Participate in the UBS Global Healthcare Conference
Madrigal, 89Bio Jump After Novo's Semaglutide Shows Promise in MASH
Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings
State Street Corp's Strategic Acquisition in 89bio Inc
89bio to Present New Analyses From ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024
89bio Negotiates $50 Million Increase in Borrowing Capacity to $150 Million
Express News | 89Bio Inc: Term Loan Matures on October 1, 2028
Express News | 89Bio Inc: Co and Certain Units Entered Into Amendment to Loan and Security Agreement
89bio (NASDAQ:ETNB) Has Debt But No Earnings; Should You Worry?
Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target